SC
SRPT icon

Sophrosyne Capital’s Sarepta Therapeutics SRPT Stock Holding History

Sophrosyne Capital’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-16,900
Closed -$345K – 87
2013
Q4 		$345K Sell
16,900
-72,500
-81% -$2.15M 0.3% 41
2013
Q3 		$4.22M Buy
89,400
+62,600
+234% +$2.41M 2.79% 12
2013
Q2 		$1.02M Buy
+26,800
New +$958K 0.8% 31

Other funds holding SRPT

Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sophrosyne Capital's SRPT Position: Q1 2014 in Review

Sophrosyne Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2014, closing a stake of 16,900 shares — an estimated $345K sold.

Sophrosyne Capital first reported a position in SRPT in Q2 2013 and held it in 3 quarters. The position peaked at $4.22M in Q3 2013. 114 funds tracked by Wall St. Rank hold SRPT as of Q1 2014.

  • Sophrosyne Capital reported no remaining Sarepta Therapeutics position as of Q1 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 16,900 Sarepta Therapeutics shares in Q1 2014, an estimated $345K.
  • Sophrosyne Capital first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 3 quarters.
  • Sophrosyne Capital's Sarepta Therapeutics position peaked at $4.22M in Q3 2013.
  • 114 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2014.

Based on Sophrosyne Capital's 13F filing for Q1 2014, filed 14 May 2014.